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FMRP loss of function causes Fragile X syndrome
(FXS) and autistic features. FMRP is a polyribo-
some-associated neuronal RNA-binding protein,
suggesting that it plays a key role in regulating
neuronal translation, but there has been little
consensus regarding either its RNA targets or mech-
anism of action. Here, we use high-throughput
sequencing of RNAs isolated by crosslinking immu-
noprecipitation (HITS-CLIP) to identify FMRP inter-
actions with mouse brain polyribosomal mRNAs.
FMRP interacts with the coding region of transcripts
encoding pre- and postsynaptic proteins and tran-
scripts implicated in autism spectrum disorders
(ASD). We developed a brain polyribosome-pro-
grammed translation system, revealing that FMRP
reversibly stalls ribosomes specifically on its target
mRNAs. Our results suggest that loss of a transla-
tional brake on the synthesis of a subset of synaptic
proteins contributes to FXS. In addition, they provide
insight into the molecular basis of the cognitive and
allied defects in FXS and ASD and suggest multiple
targets for clinical intervention.
INTRODUCTION
Fragile X syndrome (FXS) was the first genetic disorder to link
RNA regulation to human cognitive function. Loss of function
of the Fragile X mental retardation protein (FMRP) causes FXS
(Verkerk et al., 1991), the most common inherited form of intel-
lectual disability, which is further characterized by autistic
behaviors, childhood seizures, and abnormal dendritic spines
(Hagerman and Hagerman, 2002; Hernandez et al., 2009).
FMRP is an RNA binding protein (RNABP) whose function isincompletely understood, but is believed to be involved in trans-
lational regulation (Bassell andWarren, 2008; Gatto and Broadie,
2009; Costa-Mattioli et al., 2009; Zukin et al., 2009). This is of
particular interest because new protein synthesis is required
for long-term synaptic plasticity (Kelleher et al., 2004; Klann
and Dever, 2004; Richter and Klann, 2009; Sutton and Schuman,
2006), a phenomenon thought to underlie the formation and
persistence of memory (Malenka and Bear, 2004). Some
activity-regulated translational control pathways have been
identified, such as the ERK and mTOR pathways regulating initi-
ation (Hoeffer and Klann, 2010), or eEF2 phosphorylation
controlling elongation (Sutton et al., 2007), but in general these
are thought to have broad effects on translation. A specific set
of transcripts and the proteins regulating them to mediate
synaptic plasticity remain to be defined.
In the brain, FMRP is present in the neuronal cell body, prox-
imal dendrites, and axons (Christie et al., 2009) and the majority
of FMRP is associated with polyribosomes (Feng et al., 1997b;
Khandjian et al., 2004; Stefani et al., 2004).Moreover, amissense
mutation in the second RNA binding domain (I304N) abolishes
FMRP polyribosome association (Zang et al., 2009; Feng et al.,
1997a) and causes a Fragile X phenotype in mice (Zang et al.,
2009) and humans (DeBoulle et al., 1993). Studies of Fmr1
knockout (KO) and I304N mice have documented a number of
defects in synaptic plasticity (Pfeiffer and Huber, 2009; Zang
et al., 2009). These observations suggest that FMRP regulates
the translation of proteins important for proper synaptic function,
yet there is no consensus as to how it might do so. In vitro,
exogenous FMRP appears to bind and repress translation of
a variety of transcripts including reporter mRNA (Laggerbauer
et al., 2001; Li et al., 2001). In dividing fibroblast cells, it has
been suggested that transgenic Flag-tagged FMRP represses
translation during elongation, but extrapolating this finding to
endogenous FMRP in neurons is difficult (Ceman et al., 2003).
Underscoring the uncertainty of such a connection, Napoli
et al. (2008) found that nonpolyribosomal FMRP in synaptoneur-
osomes can repress translation by inhibiting cap-dependentCell 146, 247–261, July 22, 2011 ª2011 Elsevier Inc. 247
initiation through interaction with the eIF4E-BP, CYFIP1. How-
ever, this is likely to account for only a small fraction of FMRP
function in vivo as the vast majority of the protein is polyribo-
some-associated.
A key to understanding FMRP function is to identify its RNA
targets. Efforts have been made to identify specific FMRP target
mRNAs by coimmunoprecipitation (IP) and microarray analysis
(Brown et al., 2001), antibody positioned RNA amplification
(APRA) (Miyashiro et al., 2003), and bioinformatic approaches
(Brown et al., 2001; Darnell et al., 2001). However, these
approaches do not identify RNA binding sites within transcripts,
have inherent signal to noise issues (Mili and Steitz, 2004; Darnell
et al., 2005b; Licatalosi and Darnell, 2010), and are hampered by
difficulties in bioinformatic prediction of complex RNA folding
(Darnell et al., 2001, 2005a). The net result is that they have
met with limited success either in deriving a consensus set of
FMRPmRNA targets, in identifying mRNAs that can be validated
as targets in genetic systems, or in defining FMRP function.
We recently developed a general means of identifying RNA-
protein interaction sites in vivo termed crosslinking-IP (CLIP)
(Licatalosi and Darnell, 2010; Darnell, 2010). CLIP uses ultravi-
olet irradiation to penetrate tissue and create a covalent bond
between proteins and RNA molecules that are in direct contact
(within a bond-length). CLIP, particularly when combined with
high-throughput sequencing (HITS-CLIP), has been able to iden-
tify functional RNA-protein interaction sites in various contexts.
Here we have applied HITS-CLIP to the mouse brain in order
to identify FMRP-mRNA interactions. We have used the resulting
set of robust FMRP targets to drive in vitro and in vivo functional
assays that define the molecular role of FMRP in controlling
translation.
RESULTS
FMRP RNA Targets in Mouse Brain Polyribosomes
To develop FMRP CLIP (Figure 1A), we took advantage of the
observation that 85%–90%of FMRP is associatedwith polyribo-
somes in the brain (Figures 1B–1D) as a purification step (Stefani
et al., 2004). This eliminated detectable background RNA from
IPed FMRP-RNA crosslinked complexes (Figure 1E). After
RT-PCR amplification of crosslinked RNAs, products were
readily detected from wild-type (WT) but not Fmr1 KO brain (Fig-
ure 1F). Using this protocol, we performed five biologic replicates
using two independent antibodies to FMRP. To assess the spec-
ificity and reproducibility of FMRPRNAbindingwe repeatedCLIP
in biologic replicate using a second protocol (Figure 1A) cross-
linking intact brain slices, increasing the stringency of denatur-
ation, and purifying Hu:RNA complexes (Darnell et al., 2009)
from the same lysate as a control for specificity (Figures 1G–1I).
We analyzed FMRP-crosslinked RNA tags from these seven
independent experiments. Overall, 22 million tags were unam-
biguously mapped to the mouse genome, and after elimination
of PCR duplicates, 163,904 unique sequences were analyzed
(Table S1 available online). The results were very reproducible,
with high correlations seen between exonic tag number per
gene in CLIP experiments using different anti-FMRP antibodies,
purification protocols and sequencing platforms (Figures S1A
and S1B). The results were specific, as little correlation was248 Cell 146, 247–261, July 22, 2011 ª2011 Elsevier Inc.seen between FMRP mRNA targets and either Hu targets or
those of another neuronal RNABP, Nova (Figures S1C and
S1D). Importantly, the number of FMRP tags per transcript
showed little correlation with transcript abundance or length
(Figures S1E and S1F). Taken together, these data demonstrate
that FMRP reproducibly crosslinks to a subset of brain mRNAs in
a manner distinct from other neuronal RNABPs.
Identity and Functions Encoded by FMRP Target
Transcripts
We next defined the set of FMRP-mRNA interactions. We iden-
tified transcripts to which FMRP reproducibly crosslinked across
the seven independent experiments, and used the number of
unique tags per transcript in each experiment to rank the targets,
allowing us to determine a chi-square score and false discovery
rate (FDR) for each target based on rank and reproducibility.
We identified a stringent set of 842 FMRP target transcripts
(FDR < 0.01) (Tables S2A–S2C). These FMRP targets were
detectable with both antibodies (100%), using both CLIP proto-
cols (100%), different sequencing platforms (100%), and were
biologically reproducible (99% were detectable in at least six
of seven experiments). It is likely that this analysis underesti-
mates the true number of FMRP-regulated mRNAs; in addition
to the conservative FDR threshold, some targets are likely to
be rare, present in only a fraction of cells, or to interact with
FMRP only under specific conditions. Therefore the absence
of crosslinking to any one mRNA should be interpreted with
caution.
Comparison of FMRP mRNA targets with a target list previ-
ously generated using FMRP-RNA co-IP (RIP-CHIP) frommouse
brain (Brown et al., 2001) found significant overlap. Fifty-four
percent of RIP-CHIP targets (p = 2.4 3 10121; Table S2C and
Table S3A) were present in the FMRPCLIP target list, accounting
for 24% of CLIP targets. However, despite the fact that our
conditions were much more stringent than those used in RIP-
CHIP, our data conservatively identified 661 novel FMRP
mRNA targets not found previously.
We used the DAVID Bioinformatics database to analyze the
gene ontology (GO) terms assigned to them. The 842 FMRP
targets were compared with the total mRNA population present
within the polyribosomal fractions from which FMRP:RNA
complexes were captured, and independently with a database
of the transcriptome of neurons purified from mouse brain at
similar ages (Cahoy et al., 2008) (Figure 2A and Table S3B). In
both analyses, proteins encoded by FMRP-bound transcripts
were enriched in those related to neuronal and synaptic trans-
mission and regulation of small GTPase mediated signaling.
FMRP was crosslinked to multiple members of many gene fami-
lies (Table S2B).
We also compared FMRP target mRNAs to the curated data
set of mouse brain synaptic proteins (Croning et al., 2009). This
identified an especially strong overlap with the postsynaptic pro-
teome (32% of FMRP targets, p = 2.1 3 1083; Figure 2B and
Tables S3A and S3C). Strikingly, a significant fraction of the
mGluR5 (62%, p = 5.8 3 1022; Tables S3A and S3D) and
NMDAR (34%, p = 7.4 3 1023; Tables S3A and S3E) receptor
complex proteins were FMRP targets. Moreover, comparison
with a presynaptic proteome database (Abul-Husn et al., 2009)
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Figure 1. FMRP CLIP on Purified Mouse Brain Polyribosomes
(A) Schemes used for FMRP CLIP; steps specific to protocol 2 are indicated in green.
(B) Cell-equivalent aliquots of subcellular fractions from the purification steps indicated in (A) were analyzed by western blotting for FMRP (with FMRP-specific
ab17722); quantitation of three experimental replicates revealed 11.0% (standard deviation [SD] 1.4%) of FMRP is in P1.
(C) The remaining 90% of brain FMRP in S2 was applied to 20%–50% sucrose gradients and gradient fractions analyzed by western blot for FMRP.
(D) Western blot comparison of the indicated fractions from (A) demonstrated that all the FMRP in pooled polyribosomes was pelleted at 300,000 3 g.
(E) Autoradiogram of representative CLIP results from protocol 1. After dissociation of RNP complexes, samples were treated with RNase T1, FMRP was IPed,
32P-labeled linker was ligated to the 30 end of crosslinked RNA tags, RNA-protein complexes sized on SDS-PAGE, transferred and imaged by autoradiography.
32P-labeled RNA (modal size 130 kDa) in IPs from WT but not Fmr1 KO brain (bracket) were evident. Vertical line traces of each autoradiogram (blue [WT], red
[KO], and green [noncrosslinked] not shown on autoradiogram) are shown to the right.
(F) After protease digestion of the radioactive RNA-protein complexes, 50 linker was added and products amplified by RT-PCR; products of the expected size,
60–100 nucleotides, were seen after 38 cycles from WT CLIP.
(G and H) To identify complexes crosslinked to RNA of an appropriate size using Protocol 2, aliquots of lysate were treated with a serial dilution of an RNase A/T1
cocktail prior to IP of FMRP (G) or Hu (H). After 32P end-labeling, the RNA-protein complexes were imaged by autoradiography. With no RNase (0), a wide size-
range of complexes were seen, which progressively decreased as RNase increased, collapsing to the size of FMRP or Hu, as indicated (*). In the absence of
crosslinking (no XL), only trace amounts of 32P-label were present. Protein-RNA conjugates were excised from the bracketed regions of the lanes indicated with
blue arrows.
(I) Final PCR products of CLIP tags; the indicated samples were sent for Illumina sequencing.
See also Table S2 and Figure S1.
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Figure 2. Distribution of FMRP Binding Sites in Target mRNAs
(A) The top three gene ontology (GO) terms enriched in FMRP target transcripts in indicated GO categories, by p value.
(B) Overlap between the postsynaptic proteome (PSP) of the Genes2Cognition (G2C) database, the presynaptic proteome, and FMRP targets. Venn diagrams are
drawn to scale and show the overlap between FMRP target transcripts and the indicated proteomic categories, with the absolute number of evaluable transcripts
shown (p values are in Table S3A).
(C) Distribution of unique tags among FMRP or Hu target transcripts represented by pie chart or graphically (blue line; error bars represent two standard error of
the mean), normalized to the total number of FMRP or Hu target transcripts evaluable at each position (grey line), showing a predominance of FMRP tags within
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revealed that FMRP also binds mRNAs encoding approximately
one-third of the proteins in the presynaptic proteome (p =
6.4 3 1033; Figure 2B and Tables S3A and S3F). We used
Ingenuity software to identify the top pathways enriched in
FMRP targets (Figure S2A and Table S4). The most significant
overlaps included synaptic signaling pathways: synaptic long-
term potentiation, glutamate receptor signaling, neuropathic
pain signaling, GABA receptor signaling, synaptic LTD, and
CREB signaling in neurons. Intracellular signaling pathways
enriched in FMRP targets (p < 0.05) included calcium, PKA,
PLC, G protein coupled receptor, RhoA, cAMP, and PI3K/Akt
signaling pathways. This suggests a direct role for FMRP in regu-
lating translation of the pre- and postsynaptic proteome and
synaptic plasticity, likely underlying cognitive and behavioral
changes in patients with FXS, as well as epilepsy and altered
pain sensitivity (Price et al., 2007; Symons et al., 2003).
Overlap of FXS and Autism Spectrum Disorders
FXS is the leading monogenic cause of autism spectrum disor-
ders (ASDs), accounting for up to 5% of all cases (Kelleher and
Bear, 2008), and 90% of affected males show autistic behaviors
(Hernandez et al., 2009). Comparison of the 842 FMRP target
genes with 117 evaluable candidate genes from the SFARI data-
base of autism candidate genes (http://gene.sfari.org) (Basu
et al., 2009) revealed a highly significant overlap with 28 FMRP
targets (24%, p = 1.0 3 108; Table S3A), including several
well-studied autism candidate genes such NLGN3, NRXN1,
SHANK3, PTEN, TSC2, and NF1 (Table S5).
The ability of FMRP to repress translation of target mRNAs
(see below) suggests that FXS, and by extension, some cases
of ASD, may result from the overexpression of specific
dosage-sensitive genes through loss of translational suppres-
sion. Gene overexpression can occur due to copy number vari-
ations (CNVs) caused by de novo segmental duplications, and
several CNV association studies have established links to ASD
(Pinto et al., 2010; Sebat et al., 2007). We found a significant
number (25/196) of candidate autism susceptibility genes in
duplicated loci are FMRP targets (Table S3A and Table S5; p =
0.001). CNVs due to deletions showed less overlap and did not
reach significance (12/121, p = 0.28). Taken together, the overlap
between FMRP target transcripts and genes linked to the ASDs,
particularly overexpressed genes, provides a new connection
between loss of function of FMRP and the development of
autistic symptoms in patients.
FMRP Binds Coding Sequences and Stalls Ribosomes
Sixty-six percent of FMRP mRNA binding was within the coding
sequence (CDS), with no specific position relative to the start and
stop codons, and with lower tag density in the 30 or 50 UTRs. In
comparison, RNA tags of the neuronal Hu proteins mapped
predominantly to the 30 UTR of target transcripts (Figure 2C).the CDS (gold). In contrast, Hu tags were predominantly present within the 30 U
downstream 10K), a region rich in unannotated 30 UTR sequences.
(D and E) Cumulative distribution of FMRP or Hu tags, as indicated, across the len
illustrates the different mechanisms of transcript association (Hu has a specific bin
The positions of individual tags are also plotted; colors represent independent e
See also Tables S3–S5 and Figure S2.This distribution of FMRP binding could arise in a population
analysis from the sum of binding at unique positions in different
transcripts. To exclude this possibility, we examined FMRP
binding to individual targets, which also showed an even distri-
bution of tags along the CDS (Figure 2D and Figures S2B–
S2G), whereas in contrast, Hu binding to its top-ranked
targets was restricted to very specific binding sites in 30 UTRs
(Figure 2E).
The distribution of FMRP binding was unexpected. FMRP
crosslinking to the CDS is not easily reconciled with findings
that most FMRP appears to be associated with actively trans-
lating polyribosomes and that this association is sensitive to
EDTA and RNase (Stefani et al., 2004), sodium azide that blocks
initiation (Ceman et al., 2003; Feng et al., 1997a), and puromycin
(Stefani et al., 2004), an aminoacyl-tRNA analog that causes
translocating ribosomes to be released. Treating N2a cells with
puromycin or hippuristanol, an inhibitor of translation initiation,
suggested that, after ribosomal ‘‘run-off,’’ FMRPwas associated
with mRNAs still loaded with several ribosomes, in contrast to
ribosomal protein P0 (rpP0) or poly(A) binding protein (PABP)
(Figure S3A). Thus FMRP appears to associate with the CDS of
transcripts on which some of the ribosomes may be stalled.Loss of FMRP Function Relieves Ribosome Stalling
To assess the role of endogenous FMRP on translation of indi-
vidual neuronal mRNAs, we developed an in vitro translation
system programmed with endogenous brain polyribosomes
(the ‘‘IVTEBP system’’) to maintain normal RNA-protein stoichi-
ometry (Figure 3A). In the presence of puromycin at 30C, ribo-
somal run-off was evident within 2 min, plateaued by 15 min,
and was saturable, as neither a 10-fold increase in puromycin
nor incubation for up to 45 min caused additional run-off (Fig-
ure S3). No loss of polyribosome integrity was observed in
parallel reactions incubated with cycloheximide (CHX) at 30C
for up to 45 min, ruling out nuclease activity. Ribosomal run-off
could be detected in the presence of hippuristanol, reflecting
natural ribosome release at the stop codon (Figure 3B). This
run-off was accompanied by 35S-methionine incorporation in
a time- and brain polyribosome-dependent manner that was
not increased if hippuristanol was omitted (Figures S3B and
S3C), indicating that elongation can occur on pre-existing brain
polyribosome-associated mRNAs in the absence of initiation in
the IVTEBP system.
After ribosomal run-off in the presence of puromycin, FMRP
shifted in a time-dependent manner to fractions containing
approximately five to eight ribosomes, recapitulating the
behavior of FMRP in cells (Figure 3C and Figure S3A). In contrast,
PABP or Hu shifted to lighter fractions, as did FMRP when EDTA
was added to dissociate ribosomes (Figure 3C). In addition,
natural run-off occurring in the presence of hippuristanol also
resulted in retention of FMRP in large complexes in the IVTEBPTR (red) or mapped within 10,000 nt downstream of annotated genes (pink,
gth of a representative transcript.Centg1 (PIKE) is a target of both RNABPs and
ding site, whereas FMRP is evenly distributed in CDS) within one starting pool.
xperiments.
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AC
B Figure 3. FMRP Is Associated with Stalled
Polyribosomes in Elongation-Competent
Brain Extracts
(A) Schematic of the preparation of the brain-
programmed in vitro translation (IVTEBP) system, in
which S1 supernatants supplemented with amino
acids, ATP and RRL allow ribosomal runoff,
detected by analysis on sucrose gradients and
western blot of polyribosome-associated RNA
binding proteins.
(B) Gradient fractions before run-off (0 min, left
panel), or after 20 min of elongation in the pres-
ence of hippuristanol (right panel). Western blots
(middle panels) and their quantitation (bottom
graphs) were used to compare the distribution of
FMRP (blue diamonds), PABP (orange triangles),
neuronal Hu isoforms (green circles), and ribo-
somal protein P0 (red squares) in 20%–50%
sucrose gradients. A254 traces of total RNA
distribution (top panels) and gradient fractions are
shown.
(C) Gradient fractions analyzed as in (B), from
ribosomal run-offs performed before (left panels,
0 min) or after run-off in puromycin (middle panels,
20 min), or puromycin followed by 30 mM EDTA
treatment to release all ribosomes (right panels).
See also Figure S3.system (Figure 3B). Based on the results of multiple experiments,
the total amount of FMRP present on polyribosomes was not
significantly changed before and after run-off.
If FMRP regulates the translation of its mRNA targets one
might anticipate that the number of ribosomes associated
with these target transcripts would be altered in its absence.
We estimated the steady-state number of ribosomes associated
with nine FMRP target mRNAs or nine nontarget mRNAs by
analyzing transcript distribution on polyribosome gradients.
We found no reproducible differences in the sedimentation
profile of any of these mRNAs in the presence or absence of
functional FMRP in two different mouse FXS models (Figure 4,
first column, and Figure S4A). Moreover, global analysis of total
and polyribosome-associated mRNA levels identified no statisti-
cally significant changes between six pairs of Fmr1 KO and WT
littermates (other than the Fmr1 transcript itself; described in
Extended Experimental Procedures; Gene Expression Omnibus252 Cell 146, 247–261, July 22, 2011 ª2011 Elsevier Inc.[GEO] database accession number
GSE26809). These results were unex-
pected, given prior reports of FMRP-
dependent changes in mRNA polyribo-
some distribution. Although we cannot
rule out that differences such as the cell
types (e.g., human lymphoblastoid cell
lines) (Brown et al., 2001) or subcellular
fractions (e.g., synaptoneurosomes)
(Zalfa et al., 2003; Muddashetty et al.,
2007) used in these studies may account
for this discrepancy, our results clearly
demonstrate that on a cell population
level there is no FMRP-dependent differ-ence in steady state mRNA polysome distribution in the P8-P25
mouse brain.
The steady state number of ribosomes on a transcript is not
a measure of active translation. There are numerous instances
in which significant inhibition of protein synthesis is not accom-
panied by a decrease in the number of ribosomes associated
with the encoding mRNAs (Olsen and Ambros, 1999; Clark
et al., 2000; Braat et al., 2004; Nottrott et al., 2006; Maroney
et al., 2006; Petersen et al., 2006; Lytle et al., 2007). Therefore,
we separated translocating from stalled ribosomes by puro-
mycin run-off in the IVTEBP system and assessed the number
of puromycin-insensitive ribosomes remaining on target and
nontarget transcripts. In the presence of FMRP, target tran-
scripts were associated with more residual ribosomes after
run-off than in the absence of functional FMRP (WT versus
Fmr1 KO or I304N brain; Figure 4A, columns 2 and 3). Impor-
tantly, such differences were specific to FMRP-target transcripts
AB
Figure 4. Ribosomal Stalling on FMRP Target Transcripts Is Relieved in Three FMRP Loss-of-Function Models
FMRP (A) target (Map1b, Lingo1, and Kif1a) or (B) nontarget (Hprt1, Glrb, and Slc35f1) mRNA distribution in each of 16 polyribosome sucrose gradient fractions
was analyzed by qRT-PCR (see also Figure S4A). Prior to run-off (first column; CHX treated [‘‘steady-state’’] polyribosomes; second column, yellow line), no
changes inmRNA distribution were evident betweenWT (black triangles), Fmr1 KO (red squares), or I304N knock-in (orange diamonds) brain polyribosomes. The
same mRNAs were then analyzed in the IVTEBP system in puromycin to achieve run-off separating translocating from stalled ribosomes in three distinct FMRP
loss-of-function systems (Fmr1 KO [second column, red circles versus WT in black], I304N [third column, orange diamonds versus WT in black], and from WT
polyribosomes treated with kcRNA decoy to acutely disrupt FMRP polyribosome association [fourth column, red circles] compared with a nonfunctional kcRNA
point mutant [kcRNAC50G, black]). Data are plotted as a fraction of total mRNA on the gradient; error bars represent SD from three technical replicates. See also
Figure S4.(Figure 4B), suggesting that ribosomes are stalled on FMRP-
bound mRNAs in an FMRP-dependent manner in vivo, with
stalling relieved in mice harboring either of two different FMRP
loss-of-function mutations.
All three FMRP paralogs (‘‘FXRP’’ proteins FMRP, FXR1P, and
FXR2P) show significant functional redundancy in binding toRNA and polyribosomes (Darnell et al., 2009), including the
ability to be fully displaced from polyribosomes by a high affinity
in vitro selected RNA ligand (kissing complex RNA [kcRNA]; Fig-
ure S4B) (Darnell et al., 2005a). We compared the mRNA distri-
bution of FMRP target and nontarget mRNAs when WT brain
polyribosomes were acutely incubated with kcRNA duringCell 146, 247–261, July 22, 2011 ª2011 Elsevier Inc. 253
puromycin run-off. Removal of FXRPs with kcRNA but not
a nonbinding point mutant (kcRNAC50G) also resulted in apparent
relief of ribosome stalling specifically on FMRP target transcripts
(Figure 4, column 4). Significantly, addition of kcRNA after run-off
did not cause a shift in the distribution of mRNAs, ruling out the
possibility that observed changes in mRNA distributions were
due to the loss of the mass of FXRPs alone (Figure S4C). To
confirm that FXRPs stall ribosomes in vivo, we repeated the
puromycin run-off assay in N2A cells, comparing untreated
cells with loss of function by knockdown of FXR1P, FXR2P,
and FMRP (Figures S4D and S4E). The FXRP-dependent associ-
ation of target mRNAs with puromycin-insensitive ribosomes
was remarkably similar to that seen in the brain polyribosome-
programmed translation assay, underscoring the relevance of
the in vitro system to living cells. Finally, addition of EDTA to re-
move all ribosomes caused some mRNAs to migrate to lighter
fractions, consistent with the presence of residual ribosomes
on some transcripts (those with more ribosomes initially, unre-
lated to whether the transcripts were FMRP targets; Figure S5).
Taken together, these results demonstrate that acute loss of
polyribosome-associated FMRP yields the same relief of transla-
tional repression as long-term loss of function in mouse models,
indicating that ribosome stalling is likely to be caused directly
and reversibly by FMRP.
We weighted the mRNA distribution on these plots according
to the estimated number of ribosomes in each fraction (an
FMRP-dependent ribosome retention score [RRS], a measure
of the difference between the number of ribosomes remaining
on transcripts after run-off in the presence versus absence of
FMRP; Figure 5 and Figure 6A). This analysis demonstrated
a statistically significant difference between the nine FMRP
target and nine nontarget mRNAs in all three loss-of-function
models (Figure 6B). To generalize these findings, we assessed
the distribution of 39 transcripts (20 FMRP targets and a set of
comparable nontargets, controlled for length, abundance, and
neuronal expression) after run-off in the IVTEBP assay using the
kcRNA decoy (Table S6). All 39 transcripts were analyzed with
no prior assumptions, and with no exclusion of outliers. The
overall RRS scores correlated well with FMRP target binding
assessed by CLIP (c2 score, R2 = 0.53, or by tags per gene,
R2 = 0.49), and were significantly different between targets and
nontargets (Figures 6C and 6D). There was a small effect on
some nontarget transcripts, perhaps from a promiscuous asso-
ciation of FMRP with mRNAs from reassociation of FMRP with
nontargets after cell lysis and extract preparation or from exog-
enous FMRP present in the rabbit reticulocyte lysate (RRL)
(Beaulieu, 2000). Moreover, some FMRP nontargets may be
bona fide targets of FXR1/2P rather than FMRP, with ribosome
stalling also relieved by the kcRNA decoy.
The RRS was not dependent on transcript abundance (R2 =
0.01), nor the number of associated ribosomes in the steady
state (R2 = 0.07). We observed some correlation between CDS
length and RRS among all transcripts (R2 = 0.41); this was largely
due to FMRP targets (Figure 6E, R2 = 0.56 for targets; R2 = 0.17
for nontargets), consistent with FMRP stalling ribosomes across
the length of the CDS of its target transcripts. There was a signif-
icant difference in the RRS of target and nontarget mRNAs when
matched for CDS length (Figure 6F). Taken together, these data254 Cell 146, 247–261, July 22, 2011 ª2011 Elsevier Inc.provide quantitative support for the conclusion that FMRP stalls
ribosomes on transcripts to which it is directly bound.
To assess whether the relief of FMRP-dependent ribosome
stalling by kcRNA is accompanied by increased protein
synthesis, we measured 35S-methionine incorporation in the
IVTEBP assay into two FMRP targets (Camk2a and Lingo1) and
one nontarget for which we were able to quantitatively IP protein
products. We found a small but significant increase in protein
synthesis of both FMRP targets in the absence of functional
FMRP, similar to results reported for Camk2a by Osterweil
et al. (2010) in slice cultures, with no significant change in either
overall protein synthesis or in the synthesis of the nontarget
PABP (Figure 6G and Figure S6).
Characterization of the FMRP-Stalled Complex
In some studies, what were initially believed to be translocation-
blocked polyribosomes were revealed to be ‘‘pseudo-poly-
somes’’ or large mRNP complexes (Thermann and Hentze,
2007), underscoring the need for caution in making inferences
about the components of heavy complexes on sucrose gradi-
ents. To determine if the FMRP-stalled complex has the hall-
marks of a polyribosome, we first obtained electron-microscopic
(EM) images from sucrose gradient fractions after puromycin
run-off in the IVTEBP system (fractions 7–8; Figure 3C, middle
panel). These fractions harbor complexes containing multiple
ribosomes (Figure 7A) identified as such by immuno-EM on the
same gradient fraction prepared from a transgenic mouse
expressing the tagged ribosomal protein EGFP-rpL10a (Heiman
et al., 2008) (Figure 7B). To investigate the association of FMRP
with these complexes we expressed EGFP-tagged FMRP in
cells, performed a puromycin run-off experiment in vivo, and
visualized EGFP-FMRP association with these structures from
the puromycin-resistant fractions (Figure 7C and Figure S7A).
The labeling of these complexes was dependent on FMRP, rela-
tive to an overexpressed negative control (EGFP alone; Fig-
ure S7B), demonstrating the physical association of FMRP with
stalled polyribosomes in vivo (Figure 7C).
We then used micrococcal nuclease (MN) as a means of
assessing whether the FMRP stalled complex has the features
of a typical polyribosome. MN degrades the mRNA exposed
between ribosomes, dissociating polyribosomes (but not the
ribosomes themselves). Incubation of sucrose-gradient purified
polyribosomes with MN, followed by separation of ribosomes
from released material on a sucrose cushion, revealed that the
majority of FMRP pelleted with the ribosomes (Figures 7D and
7E). As controls, PABP (bound to mRNA poly(A) tails) was readily
released from polyribosomes by MN, whereas rpP0 was MN
resistant. Surprisingly, sizing of the puromycin-resistant, MN-
treated complex revealed that FMRP remained associated with
the large complex up to 1 U/ul MN. At very high MN concentra-
tions (20 U/ul, used to cleave between SRP-associated stacked
ribosomes) (Wolin and Walter, 1988), FMRP is partially released
to light fractions, although a substantial fraction (60%) remains
associated with the complex (Figure 7F). Taken together, these
results suggest a close association of FMRP with ribosomes
that are stacked or condensed in such a way as to largely
prevent MN from cleaving between either FMRP and the ribo-
somes or between the ribosomes themselves. Consistent with
Figure 5. Ribosome-Weighted mRNA Profiles for FMRP Targets and Nontargets
Ribosome-weighted graphs of kcRNA decoy data from Figure 4 are replotted, along with additional examples, weighting for the number of ribosomes in each
fraction, as (fraction of mRNA) 3 (no. of ribosomes per fraction) (from Figure 6A).
(A) Ribosome-weighted graphs of the top 12 (by RRS) of 21 FMRP target mRNA profiles.
(B) Ribosome-weighted graphs of 12 FMRP nontarget mRNAs. Data for all 39 transcripts is in Table S6. Error bars represent SD from three technical replicates.
See also Table S6 and Figure S5.this interpretation, we found that the ultrastructure of the polyri-
bosomal complexes in the MN-treated fractions was indistin-
guishable from those in untreated fractions (Figure 7G versus
Figure 7A).
To determine whether FMRP, ribosomes and repressed FMRP
target mRNAs are indeed in the same macromolecular complex
in the brain, antibodies against rpP0 were used to IP ribosomes
from puromycin- and MN-resistant complexes purified onsucrose gradients. FMRP co-IPed with rpP0-containing com-
plexes, as did the ribosomal proteins rpL5 and rpS6 (Figure 7H),
demonstrating a direct association of FMRPwith ribosome-con-
taining complexes, reminiscent of previous findings in cultured
cells (Khandjian et al., 1996; Siomi et al., 1996).
To directly assess FMRP interaction with mRNA in the stalled
complexes, we performed FMRP HITS-CLIP on polyribosomes
crosslinked after puromycin- run-off in the IVTEBP system. InCell 146, 247–261, July 22, 2011 ª2011 Elsevier Inc. 255
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Figure 6. Quantitation of FMRP-Mediated Ribosome Stalling
(A) Analysis of sucrose gradients used in RRS calculations. Top: the percent sucrose (w/w) measured in each gradient fraction using a refractometer was linear
with fraction number (R2 = 0.99). Fractions 1 and 2 correspond to lysate. Bottom: determination of the approximate number of ribosomes (open circles) in sucrose
gradient fractions by extrapolation from those that can be directly counted (black circles), using linear regression analysis (R2 = 0.999), based on the linearity
determined in the top panel.
(B) Bar graphs plotting RRS scores in three different FMRP loss of function models (I304N, KO, kcRNA decoy) for nine target (gold) and nine nontarget (red)
transcripts. Significant differences are evident between targets and nontargets in all three systems, as well as a significantly greater effect of kcRNA decoy than
either genetic FMRP loss of function model. Error bars depict the standard error of the mean (SEM).
(C) FMRP binding to target mRNAs (c2 score) compared with a functional assay (RRS) showed a significant correlation for 39 tested transcripts. Target
transcripts (shaded gold) showed high c2 and RRS scores relative to nontargets (shaded red), with some outliers and two targets deemed to be in a ‘‘grey
zone’’ (see Table S6). Two transcripts, Arc and Gria1 mRNA, are in the ‘‘grey zone.’’ Arc falls just below the FDR < 0.1 cutoff for the robust FMRP target
list, likely in part because of very low abundance in resting mice (Table S6). Neither was included in statistical analyses of FMRP targets versus nontargets
in (D).
(D) Twenty FMRP targets and 16 nontargets show a significant difference in RRS (RRSAvg(target) = 148.1 +/ 14.6; RRSAvg(nontarget) = 58.3 +/ 8.9; p = 9.73 106).
This analysis includes every mRNA tested except Arc and Gria1.
(E) RRS is highly correlated with CDS length for FMRP targets (excluding an outlier, Bsn; CDS 11,829 nts).
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parallel, CLIP was done on polyribosomes taken from the
steady-state (CHX) in the IVTEBP system. In two biological
replicate CLIP experiments, we found that FMRP was cross-
linked to the same target transcripts (Figure 7I and Table S7)
and with the same CDS distribution (Figure 7J). Taken together,
the most judicious interpretation of these experiments is that
FMRP represses translation on polyribosomes in a large com-
plex consisting of target mRNAs and stalled ribosomes.
DISCUSSION
Understanding the pathophysiology of Fragile X syndrome and
its extensive overlaps with autism offers the hope of gaining
insights into the molecular basis of cognition and behavior.
FMRP has been hypothesized to inhibit translation of mRNAs
encoding ‘‘plasticity-related proteins’’ (Bear et al., 2004), and
autism can be caused bymutations in proteins that normally limit
translation (Kelleher and Bear, 2008). Here we provide a molec-
ular basis for the overlap between FXS, autism and defects in
synaptic plasticity by first showing that many transcripts bound
by FMRP encode plasticity-related and other synaptic proteins,
and by demonstrating that FMRP represses their translation
by stalling ribosomal translocation. These results overlay unbi-
ased, genome-wide target identification with direct biochemical
assays of endogenous interactions; although they cannot
describe FMRP function on every individual candidate transcript,
they provide a statistically robust model for the predominant
action of FMRP in translational regulation (Figure S7C).
Our data support a model in which FMRP acts to stall ribo-
somal translocation during elongation as part of a complex con-
taining target mRNAs and ribosomes, analogous to the action of
SRP (Wolin and Walter, 1988). It is increasingly recognized that
a large fraction of cellular mRNA may be translated within
subcellular domains (Martin and Ephrussi, 2009), and our data
are consistent with FMRP playing a role in controlling such
processes. Translational repression by ribosome stalling and
stacking may confer several advantages to FMRP in regulating
neuronal translation. It may permit translocation to distal sites
of protein synthesis (Krichevsky and Kosik, 2001) while protect-
ing mRNA from degradation, allow rapid protein synthesis in
response to synaptic activation, as seen in response to local
application of BDNF (Aakalu et al., 2001), and immediately
slow protein production while recycled ribosomes continue to
re-initiate and restore the ‘‘loaded’’ state (Figure 7C) (Wolin and
Walter, 1988). Although the molecular mechanism by which
FMRP stalls ribosomes remains to be determined, it is likely to
be dynamic, as it can be acutely reversed by RNA decoys in
run-off assays. Such reversibility could be mediated in vivo by
FMRP phosphorylation, which has been hypothesized to regu-
late FMRP’s association with apparently stalled polyribosomes
in mouse fibroblasts (Ceman et al., 2003), by FMRP degradation(F) Six FMRP targets and seven nontargets matched for length (in the 1–2 kbp
RRSAvg(nontarget) = 44.8 +/ 8.6; p = 0.040).
(G) 35S-methionine labeled protein synthesized from two FMRPmRNA targets (Ca
IVTEBP system were compared by IP, SDS-PAGE, and Phosphor Imaging, normal
bars represent SEM in all panels, and p values were determined using a two-tail
See also Table S6 and Figure S6.(Hou et al., 2006), or other means. Agents such as antibiotics that
slow ribosomal translocation may help restore the brake on
translation lost in FXS, and may be of worthy of clinical
consideration.
Although much attention has been paid to the role of FMRP in
regulating Hebbian synaptic plasticity through the control of
local translation, the bulk of the protein is in the cell body (Christie
et al., 2009). Moreover, FMRP regulates many mRNAs that are
probably not localized to the synapse: for example, Bsn and
Pclo mRNAs encode proteins that are synthesized in the cell
body and transported to the synapse as a complex (Shapira
et al., 2003). These observations suggest that FMRP may play
a role in homeostatic synaptic plasticity (Turrigiano, 2008). In
this model, FMRPwould act to repress the translation stimulated
by neuronal activity to generate a feedback loop limiting
neuronal responses to activity at the level of the neuron rather
than a specific synapse.
In contrast to HITS-CLIP studies that have identified regulatory
sites involved in RNA processing (Licatalosi and Darnell, 2010;
Darnell, 2010), FMRP HITS-CLIP revealed a different and unex-
pected mode of protein-RNA interaction. We did not identify
binding to specific sites suggested by in vitro FMRP RNA selec-
tion experiments (G-quadruplex or kissing complex motifs) (Dar-
nell et al., 2001, 2005a; Schaeffer et al., 2001). Moreover, using
the RNABob motif-finding program (Darnell et al., 2001), we
found that bioinformatically predicted G-quadruplex motifs are
no more abundant in the set of 842 robust FMRP target mRNAs
than in an equivalent set of 842 nontargets (controlled for
neuronal expression and length; 1112 versus 1068, or 43%
versus 39% of targets versus controls, respectively). Indeed,
previous studies have shown that the RGG box is not necessary
for polyribosome association (Darnell et al., 2005b) and G-quad-
ruplex RNA ligands cannot compete FMRP off polyribosomes
(Darnell et al., 2005a). How FMRP associates with a specific
set of mRNAs remains unclear; FMRP may bind to occult RNA
motifs, be redistributed on target mRNA, and/or be recruited to
targets via protein-protein interactions.
The proteins encoded by FMRP target mRNAs control the
balance of activity-dependent translation in synaptic plasticity.
They include mGluR5 and the NMDAR subunits and many other
components of their macromolecular complexes at the synapse,
consistent with the finding that mGluR and NMDAR-dependent
synaptic plasticity are altered in FXS mouse models (Harlow
et al., 2010; Pilpel et al., 2009). FMRP also regulates the expres-
sion of components of the ERK and mTOR signal transduction
pathways that convert receptor activity into translational output,
and many downstream pre- and postsynaptic structural, scaf-
folding, catalytic, receptor, and channel proteins that are likely
to be final determinants of changes in synaptic strength.
FMRP target mRNAs are a valuable data set for considering
pharmacologic therapy for FXS. mGluR5 inhibitors have shownwindow) show a significant difference in RRS (RRSAvg(target) = 93.7 +/ 17.6;
mk2a and Lingo1; gold shading) or one nontarget (Pabpc1; red shading) in the
izing against irrelevant bands in the IP and a CHX-treated control sample. Error
ed Student’s t test.
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Figure 7. Characterization of the FMRP-Stalled Complex
(A) EM images of sucrose gradient fractions after puromycin-induced run-off of translocating ribosomes (as in Figure 3C). Negative staining with uranyl acetate
revealed structures confirmed to be polyribosomes in (B).
(B) Sucrose gradients were prepared from cerebellum of the Purkinje cell-specific Pcp2-promoter driven EGFP-tagged rpL10a BAC transgenic mice (Heiman
et al., 2008), and polyribosome fractions were treatedwith 6 nM gold-labeled anti-EGFP antibody and processed for EM. Specific staining on clustered structures
is indicated (white arrows). Only1%of polyribosomes showed labeling, consistent with the use of whole cerebellum for analysis, and indicating specificity of the
immunogold label.
(C) Immuno-EM images of EGFP-FMRP association with stalled polyribosomal complexes after puromycin run-off in vivo in transfected cells. EGFP-FMRP was
detected using 12 nm gold-labeling and antibodies against EGFP. 13.5% of polyribosomes were labeled in the presence of EGFP-FMRP (n = 500) whereas only
0.02% of polyribosomes from EGFP-expressing cells were associated with gold (n = 500).
(D and E) Western blot (WB) analysis (D) and quantitation (E) of the micrococcal nuclease (MN) resistance of FMRP and ribosome co-sedimentation. Poly-
ribosome-containing sucrose gradient fractions of mouse brain extracts were treated with (+) or without () 1000 U/ml MN, centrifuged through 15%–20%
sucrose, separating proteins as released supernatant (S) or heavy pelleted (P) particles, which were analyzed for the indicated proteins by WB. Error bars
represent standard deviation of three independent experiments.
(F) Brain extracts were subjected to puromycin run-off, treated with the indicated concentration of MN, purified on 20%–50% sucrose gradients and the indicated
proteins analyzed by TCA precipitation and WB; only 25% of fractions 1–3 were precipitated to compensate for their high protein concentrations. Bottom:
quantitation of FMRP from samples treated with the indicated concentrations of MN. Signals in lanes 1–3 were multiplied by 4 to compensate for the amount
precipitated.
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some clinical efficacy, and NMDAR antagonists may also be
worthy of clinical consideration. FMRP also targets ERK1 and
the mTOR inhibitors Pten, Nf1, and Tsc2, proteins closely linked
to autism, supporting the possibility that pharmacologic agents
acting on the mTOR and ERK pathways may be clinically
relevant for FXS and autism (Hoeffer and Klann, 2010; Kelleher
and Bear, 2008). However, FMRP also targets the PI3K-
enhancer PIKE (Centg1), and PIKE overexpression in FMRP
null mice results in elevated PI3K signaling to themTOR pathway
(Sharma et al., 2010), indicating the need for care in translating
these findings into therapy.
Themolecular basis for the overlap in symptoms between FXS
and autism is poorly understood. The overlap between FMRP
targets and the current list of autism susceptibility genes and
loci is extensive and sheds light on common pathways, support-
ing the hypothesis that synaptic dysfunction is critical to the
development of autistic features common to both disorders
(Kelleher and Bear, 2008). FMRP and ASD targets fall into
several functional categories (Sebat et al., 2007; Pinto et al.,
2010), including synaptic cell adhesion molecules, the NMDAR
complex, the mTOR pathway, and regulators of small GTPases.
The FMRP target list also provides a valuable tool for focusing
attention on specific gene candidates within multigenic loci for
ASD. The three most common syndromic duplications linked
to ASD each contain between 13–28 protein-coding genes and
harbor at least one FMRP target gene (Table S5). Moreover,
two well-studied candidate genes present in the 17p11.2 and
15q11–13 duplications, Rai1 and Ube3a, harbored FMRP CLIP
tags in six of seven and three of seven experiments, respectively;
their extremely low expression levels in brain polyribosomesmay
have precluded their inclusion on the statistically robust FMRP
target list. Although the FMRP target set disproportionately over-
laps amplified versus deleted ASD-related CNVs, they include
genes whose loss results in autism. This is consistent with the
gene balance hypothesis, which posits that the same phenotype
can arise from under- or overexpression of dosage-sensitive
proteins because either disrupts stoichiometry of the same
complex (Conrad and Antonarakis, 2007). Taken together, the
relationship between FMRP target transcripts and genes linked
to the ASDs, particularly overexpressed genes, provides a new
connection between loss of function of FMRP and the develop-
ment of autistic symptoms in patients.EXPERIMENTAL PROCEDURES
Mice used as experimental controls were littermates, and experimental results
were reproduced in multiple independent experiments as noted throughout.(G) Samples from (A) were treated with 1000 U/ml MN prior to sucrose gradient
(H) Samples prepared as in (G) fromWT or Fmr1 KO brain were IPed with anti-rpP
indicated proteins by WB.
(I) Correlation of tags/transcript pooled from two biologic replicate FMRP CLIP e
mycin run-off) brain polyribosomes.
(J) Representative results from the experiments in (I) showing CLIP tag distribution
of 10 genes assessed; comparison of steady-state tags [blue] and stalled comple
50UTR blue, 30UTR red). Biochemical purification, including co-IP and nuclease se
EM in two to three independent experiments, respectively, and CLIP on the stall
See also Table S7 and Figure S7.Male wild-type and Fmr1tm1Cgr (Fmr1 KO) mouse brain (P11–P25) was used
for polyribosome CLIP experiments as described in Extended Experimental
Procedures. After high-throughput sequencing, unique CLIP tags were identi-
fied and mapped to the mouse mm9 genomic database or RefSeq transcripts.
FMRP targets were ranked using a nonparametric method that considered
both the total number of tags per gene in each of the seven different CLIP
experiments and experimental reproducibility.
GO functional category enrichment was analyzed using DAVID 6.7 software.
Transcript abundance on polyribosomes was determined from RNA obtained
from six littermate pairs of wild-type and Fmr1tm1Cgr mice (FVB background,
P8 males), and data analyzed with Mouse 430 2.0 Gene chips using gcRMA
in Bioconductor, as described in Extended Experimental Procedures. FMRP
target pathway analysis used the core analysis module of the Ingenuity Path-
ways Analysis (IPA) knowledge base (http://www.ingenuity.com).
The IVTEBP system was generated from postnuclear brain extracts mixed
with ATP, amino acids, and RRL, and ribosomes were run-off in the presence
of puromycin or hippuristanol or allowed to continue natural elongationwithout
additions. mRNA distribution on sucrose gradients was quantitated by qRT-
PCR on an iQ5 Multicolor Real-Time PCR Detection System (BioRad). Exper-
iments gave reproducible results in four of four, two of two, and one biologic
replicate with kcRNA decoy, I304N mice, and KO mice, respectively. In sum,
these results were consistent in seven of seven experiments using three
loss-of-function models.ACCESSION NUMBERS
Microarray data were deposited in the GEO database with accession number
GSE26809.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and seven tables and can be found with this article online at doi:
10.1016/j.cell.2011.06.013.
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xes [green]). Individual tags are shown below the mRNA cartoon (CDS is gold,
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